Feasibility study of a combined insulin‐delivery and glucose sensor system worn over 7 days in persons with type 1 diabetes
Authors' conclusion
This human feasibility study supports the potential of CGM-IS use for up to 7 days with a mean survival of over 6 days. However, our data indicate that the durability of insulin delivery and sensor refinement are required prior to commercialisation.
Study context
- Population
- Adults with T1D using insulin pumps and continuous glucose monitoring (CGM); 7 days with three meal test days and four free living days
- Participants
- 40 adults
- Outcome
- Sensor accuracy (MARD) and infusion set function (TIR, mean sensor glucose, total daily dose of insulin)
- Follow-up
- 7-day wear
Methodological detailssingle centre, single arm, non-randomised
- Single centre
- Single arm
- Non-randomised
Main finding
As reported in the abstract
- Sensor mean average relative difference (MARD), Day 1
- 16.4%
- Sensor MARD, Day 4
- 14.8%
- Sensor MARD, Day 7
- 17.7%
- Readings meeting 15/15 criterion for blood glucose (BG) readings <70.2 mg/dL
- 60.0%
- Total daily dose (TDD) increase at Days 5-6
- 7.3 units/day (16%)
- Mean BG increase at Days 5-6
- 16.2 mg/dL (10.2%)
- Time in range (TIR) fall at Days 5-6
- −7.8% (11.2%)
Further findings
Device survival and wear time
- Devices lasting >4 days
- 92.1%
- Mean wear time
- 6.3 ± 1.4 days
Safety
Tolerability
- The device was well tolerated
Original publication
Feasibility study of a combined insulin‐delivery and glucose sensor system worn over 7 days in persons with type 1 diabetes. Diabetes Obes Metab. Published 25 November 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →